Biontech

Biontech Current Assets

The Current Assets of Biontech (BNTX) as of Nov 15, 2026 is 284.50 M EUR. In the previous year, Current Assets was 2.02 B EUR — a change of -85.92% (lower).

Current Assets

284.50 MEUR

YoY

-85.92%

Last updated:

Current Assets of Biontech is 2025 284.50 M EUR. Current Assets of Biontech was 2024 2.02 B EUR. It decreases by -85.92% lower compared to the previous year.

The Biontech Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2018
36.42 M EUR
Jan 1, 2019
39.12 M EUR
Jan 1, 2020
324.10 M EUR
Jan 1, 2021
13.00 B EUR
Jan 1, 2022
7.86 B EUR
Jan 1, 2023
2.98 B EUR
Jan 1, 2024
2.02 B EUR
Jan 1, 2025
284.50 M EUR
The Biontech Current Assets history
YEARCurrent AssetsYoY
284.50 MEUR-85.92%
2.02 BEUR-32.18%
2.98 BEUR-62.10%
7.86 BEUR-39.55%
13.00 BEUR+3,910.46%
324.10 MEUR+728.54%
39.12 MEUR+7.41%
36.42 MEUR+73.24%
21.02 MEUR+325.48%
4.94 MEUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biontech Stock analysis

What does Biontech do? BioNTech SE is a German biotech company specializing in the development of innovative therapies for cancer and other serious diseases. The company was founded in 2008 by Ugur Sahin and Özlem Türeci and is headquartered in Mainz. History: BioNTech was established to develop novel treatment options for cancer patients. Originally started as a pure research company, the company has since evolved into a global leader in mRNA-based therapeutics. In recent years, BioNTech has entered into numerous collaborations and partnerships with renowned pharmaceutical companies and other research institutions to strengthen its innovative power and competitiveness. Business model: BioNTech's business model involves developing novel mRNA-based therapeutics for the treatment of cancer and other serious diseases. The company relies on close collaboration with other research institutions and pharmaceutical companies to leverage the latest scientific knowledge and technologies. BioNTech aims to bring its therapeutics to market as quickly as possible to enable more effective treatment for patients worldwide. Divisions: BioNTech is divided into various divisions to optimize its research activities. One of the most important divisions is cancer research, in which the company specifically seeks new treatment options for various types of cancer. BioNTech focuses on the development of personalized cancer immunotherapy tailored to the individual needs of each patient. In this context, the company works closely with other researchers and oncologists to achieve the best possible outcomes. Another important area of BioNTech is vaccine development. The company uses mRNA technology to rapidly and effectively develop vaccines against various infectious diseases. In 2020, BioNTech, together with the US pharmaceutical company Pfizer, brought the first mRNA vaccine against COVID-19 to the market, which has high efficacy and safety. This technology enables rapid response to new pathogens and targeted vaccine development. Products: BioNTech offers a variety of therapeutics and vaccines based on mRNA technology. One of the company's most important products is the mRNA vaccine against COVID-19, which is in use worldwide. In addition, BioNTech develops personalized cancer immunotherapies tailored to the individual characteristics of patients' tumors. Another product of BioNTech is mRNA immunotherapies that can be used for various autoimmune diseases. Conclusion: BioNTech is an innovative biotech company specializing in the development of mRNA-based therapeutics for the treatment of cancer and other serious diseases. With its business model that relies on collaborations and partnerships, the company is able to rapidly and effectively respond to new challenges while staying scientifically up to date. BioNTech has brought a variety of products to the market in a short period of time that have high efficacy and safety, thereby helping patients worldwide. Answer: BioNTech is a German biotech company that specializes in the development of mRNA-based therapeutics for the treatment of cancer and other serious diseases. Biontech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biontech stock

Current Assets of Biontech is 284.50 M EUR in 2025.

Current Assets of Biontech changed from 2.02 B EUR to 284.50 M EUR, representing a -85.92% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Assets Biontech since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's Biontech historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Biontech

All Key Metrics — Biontech